205 related articles for article (PubMed ID: 14709942)
1. Platelet serotonergic predictors of clinical improvement in obsessive compulsive disorder.
Delorme R; Chabane N; Callebert J; Falissard B; Mouren-Siméoni MC; Rouillon F; Launay JM; Leboyer M
J Clin Psychopharmacol; 2004 Feb; 24(1):18-23. PubMed ID: 14709942
[TBL] [Abstract][Full Text] [Related]
2. Platelet serotonergic markers as endophenotypes for obsessive-compulsive disorder.
Delorme R; Betancur C; Callebert J; Chabane N; Laplanche JL; Mouren-Simeoni MC; Launay JM; Leboyer M
Neuropsychopharmacology; 2005 Aug; 30(8):1539-47. PubMed ID: 15886722
[TBL] [Abstract][Full Text] [Related]
3. Platelet serotonin transporter in children and adolescents with obsessive-compulsive disorder or Tourette's syndrome.
Sallee FR; Richman H; Beach K; Sethuraman G; Nesbitt L
J Am Acad Child Adolesc Psychiatry; 1996 Dec; 35(12):1647-56. PubMed ID: 8973072
[TBL] [Abstract][Full Text] [Related]
4. Decreased platelet 3H-paroxetine binding in obsessive-compulsive patients.
Marazziti D; Rossi A; Gemignani A; Giannaccini G; Pfanner C; Milanfranchi A; Presta S; Lucacchini A; Cassano GB
Neuropsychobiology; 1996; 34(4):184-7. PubMed ID: 9121618
[TBL] [Abstract][Full Text] [Related]
5. Changes in platelet markers of obsessive-compulsive patients during a double-blind trial of fluvoxamine versus clomipramine.
Marazziti D; Pfanner C; Palego L; Gemignani A; Milanfranchi A; Ravagli S; Lensi P; Presta S; Cassano GB
Pharmacopsychiatry; 1997 Nov; 30(6):245-9. PubMed ID: 9442546
[TBL] [Abstract][Full Text] [Related]
6. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial.
Denys D; Van Nieuwerburgh F; Deforce D; Westenberg HG
J Clin Psychiatry; 2007 May; 68(5):747-53. PubMed ID: 17503984
[TBL] [Abstract][Full Text] [Related]
7. Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene.
Billett EA; Richter MA; King N; Heils A; Lesch KP; Kennedy JL
Mol Psychiatry; 1997 Sep; 2(5):403-6. PubMed ID: 9322235
[TBL] [Abstract][Full Text] [Related]
8. Platelet imipramine binding and serotonin uptake in obsessive-compulsive patients.
Vitiello B; Shimon H; Behar D; Stoff D; Bridger WH; Friedman E
Acta Psychiatr Scand; 1991 Jul; 84(1):29-32. PubMed ID: 1927563
[TBL] [Abstract][Full Text] [Related]
9. Platelet serotonergic binding sites in alcohol-dependent patients.
Arranz B; Rosel P; Sarró S; Zaldivar E; Cano R; Navarro MA; San L
Alcohol Alcohol; 1999; 34(5):726-32. PubMed ID: 10528815
[TBL] [Abstract][Full Text] [Related]
10. The putative catalytic role of higher serotonin bioavailability in the clinical response to exposure and response prevention in obsessive-compulsive disorder.
Sampaio T; Lima C; Corregiari F; Bernik M
Braz J Psychiatry; 2016; 38(4):287-293. PubMed ID: 27798711
[TBL] [Abstract][Full Text] [Related]
11. Association between serotonergic candidate genes and specific phenotypes of obsessive compulsive disorder.
Denys D; Van Nieuwerburgh F; Deforce D; Westenberg HG
J Affect Disord; 2006 Mar; 91(1):39-44. PubMed ID: 16443280
[TBL] [Abstract][Full Text] [Related]
12. Altered serotonin function in suicide. Evidence from platelet and neuroendocrine studies.
Pandey GN
Ann N Y Acad Sci; 1997 Dec; 836():182-200. PubMed ID: 9616799
[TBL] [Abstract][Full Text] [Related]
13. Platelet [3H]paroxetine binding in patients with OCD-related disorders.
Marazziti D; Dell'Osso L; Presta S; Pfanner C; Rossi A; Masala I; Baroni S; Giannaccini G; Lucacchini A; Cassano GB
Psychiatry Res; 1999 Dec; 89(3):223-8. PubMed ID: 10708268
[TBL] [Abstract][Full Text] [Related]
14. Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.
Humble MB; Uvnäs-Moberg K; Engström I; Bejerot S
BMC Psychiatry; 2013 Dec; 13():344. PubMed ID: 24359174
[TBL] [Abstract][Full Text] [Related]
15. Serotonin transporter and seasonal variation in blood serotonin in families with obsessive-compulsive disorder.
Hanna GL; Himle JA; Curtis GC; Koram DQ; Veenstra-VanderWeele J; Leventhal BL; Cook EH
Neuropsychopharmacology; 1998 Feb; 18(2):102-11. PubMed ID: 9430134
[TBL] [Abstract][Full Text] [Related]
16. Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine.
Alvarez JC; Gluck N; Arnulf I; Quintin P; Leboyer M; Pecquery R; Launay JM; Perez-Diaz F; Spreux-Varoquaux O
Clin Pharmacol Ther; 1999 Dec; 66(6):617-24. PubMed ID: 10613618
[TBL] [Abstract][Full Text] [Related]
17. Increased density of the platelet serotonin transporter in autism.
Marazziti D; Muratori F; Cesari A; Masala I; Baroni S; Giannaccini G; Dell'Osso L; Cosenza A; Pfanner P; Cassano GB
Pharmacopsychiatry; 2000 Sep; 33(5):165-8. PubMed ID: 11071017
[TBL] [Abstract][Full Text] [Related]
18. Clinical predictors of drug nonresponse in obsessive-compulsive disorder.
Shetti CN; Reddy YC; Kandavel T; Kashyap K; Singisetti S; Hiremath AS; Siddequehusen MU; Raghunandanan S
J Clin Psychiatry; 2005 Dec; 66(12):1517-23. PubMed ID: 16401151
[TBL] [Abstract][Full Text] [Related]
19. No difference between platelet serotonin--5-HT(2A) receptors from children with and without ADHD.
Pornnoppadol C; Friesen DS; Haussler TS; Glaser PE; Todd RD
J Child Adolesc Psychopharmacol; 1999; 9(1):27-33. PubMed ID: 10357515
[TBL] [Abstract][Full Text] [Related]
20. Decreased platelet imipramine binding in Tourette syndrome children with obsessive-compulsive disorder.
Weizman A; Mandel A; Barber Y; Weitz R; Cohen A; Mester R; Rehavi M
Biol Psychiatry; 1992 Apr; 31(7):705-11. PubMed ID: 1318082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
